Navigation Links
HCA Reports Fourth Quarter and Year End 2008 Results
Date:2/3/2009

Emergency Room Visits 1,276,900 1,288,300 5,246,400 5,116,100 % Change -0.9% 2.5% Outpatient Revenues as a Percentage of Patient Revenues 37.5% 36.9% 37.4% 36.9% Average Length of Stay 4.9 4.9 4.9 4.9 Occupancy 52.7% 52.7% 54.1% 53.9% Equivalent Occupancy 81.5% 80.3% 82.9% 81.7% Same Facility: Admissions 375,200 373,500 1,515,900 1,502,700 % Change 0.5% 0.9% Equivalent Admissions 578,900 568,500 2,319,300 2,276,600 % Change 1.8% 1.9% Revenue per Equivalent Admission $12,338 $11,768 $11,990 $11,411 % Change 4.8% 5.1% Inpatient Revenue per Admission $11,761 $11,139 $11,361 $10,738 % Change 5.6% 5.8% Inpatient Surgery Cases 120,400 121,300 485,800 488,400 % Change -0.7% -0.5% Outpatient Surgery Cases 198,200 196,100 783,800 785,200 % Change 1.1% -0.2% Emergency Room Visits 1,255,200 1,252,000 5,128,700 4,952,000 % Change 0.3% 3.6% Number of Consolidating and Nonconsolidating (Equity Joint Ventures) Hospitals: Consolidating 158 161 158 161 Nonconsolidating (Equity Joint Ventures) 8 8 8 8 Total Number of Hospitals 166
'/>"/>
SOURCE HCA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Perrigo Reports Record Second Quarter Sales
2. Rochester Medical Reports First Quarter Results
3. Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009
4. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
5. Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009
6. Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009
7. MDS Files 2008 Annual Reports
8. North State Bancorp Reports Profitable 2008
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009
10. Cardiums InnerCool Reports on Expanding Use of Therapeutic Hypothermia
11. Zimmer Reports Fourth Quarter and 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... This report studies the global ... forecast period of 2014 to 2019. This market ... 6.5% from 2014 to 2019. , Further Inquiry ... the global pharmacovigilance and drug safety software market ... basis of functionality, namely, adverse event reporting software, ...
(Date:3/30/2015)... On March 19th, 2015, in the ... the Detroit Lions, LiveToBeSober.org hosted the “Fighting Addiction Together” ... and bishops as well as other civic leaders and ... the luncheon, including retired Detroit Lions wide receiver Herman ... two survivors of their own personal battles with addiction, ...
(Date:3/30/2015)... Dr. Shahdad Arami is now ... receive $200 off their Invisalign treatment. Many people crave ... a mouthful of metal. Invisalign offers an alternative. According ... is effective for straightening teeth but has no aesthetic ... oral appearance. The Invisalign system allows both teenagers and ...
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition ... current Epax® Ultra and Core concentrates manufactured in ... certification ensures the manufacturing process and all physical ... regulations for Halal. , The new Halal ... further advance its customer service to a global ...
(Date:3/30/2015)... Los Angeles, CA (PRWEB) March 30, 2015 ... its traditional blue polo for yellow to inspire courage ... who suffers from Severe Combined Immunodeficiency (SCID). SCID causes ... a bone marrow transplant is needed to allow the ... his second transplant last Friday, created a video with ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2
... HRAL) announced that it has received additional licenses from,Wal-Mart ... WMT ), to open their ninth and tenth ... #3195 located at 1070 Major,Mackenzie Drive in Richmond Hill ... Y006A in Markham will both officially open today. This,expansion ...
... ... 2008 Guidance Amedisys to Host ... Amedisys, Inc.,(Nasdaq: AMED ) ("Amedisys" or "the Company"), one of America,s ... September 30, 2007: Three-Month Periods Ended September 30, 2007 and 2006, ...
... Pieris AG,(Munich, Germany) and Pepscan ... of a research collaboration aimed at ... (GPCRs) and their,development as therapeutic candidates. ... next generation targeted,therapeutics with clear advantages ...
... Oct. 30 CryoLife, Inc. (NYSE: CRY ),a ... Scott B. Capps has been named vice president, clinical ... vice president and,general manager of CryoLife Europa, Ltd., based ... CryoLife in 1995 and has held several positions with,the ...
... at launch, due to its First To File ... ... owned subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL has received tentative ... 40 mg,80 mg, 160 mg and 320 mg. Total annual market sales for ...
... to Mouth Guards, GLENDALE, Calif., Oct. 23 ... to pay as much attention to,you oral health as ... concerned about their total health, weight issues and,being healthy, ... health of,their mouth," said Jean Honny, president of the ...
Cached Medicine News:Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 2Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 2Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 4Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 5Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 6Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 7Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 8Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 9Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 10Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 11Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 12Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 13Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 14Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 15Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 2Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 3Health News:CryoLife Announces Additions to Management Team 2Health News:Ranbaxy Receives Tentative Approval For Valsartan Tablets 2Health News:California Dental Hygienists Offer Health Tips for Weekend Warriors & Fitness Buffs 2
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences ... the primary efficacy endpoint in the Phase 3 ... placebo for the treatment of painful diabetic neuropathy ... endpoints showed statistically significant improvement over placebo.  In ... was observed.  The results of this trial provide ...
(Date:3/29/2015)... TITUSVILLE, N.J. , March 29, 2015 /PRNewswire/ ... delayed time to relapse compared to placebo in ... 3 clinical study published this week in the ... (JAMA) Psychiatry . Results of ... recent New Drug Application (NDA) filing for three-month ...
(Date:3/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... the issuance of an aggregate of 30,000 stock options ... aggregate of 120,500 stock options to employees and consultants ... three years and will be exercisable for a period ... per stock option. About Covalon Covalon ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
... , PRINCETON, N.J. and SAN DIEGO, ... biotechnology company committed to research and product discovery for ... announced results from an in vitro study evaluating TBR-652 ... tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the ...
... PARIS and TARRYTOWN, N.Y., Sept. 11 Sanofi-aventis ... Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced the ... Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line ... by an Independent Data Monitoring Committee (IDMC). As part ...
Cached Medicine Technology:Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 3Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 5
Implex cemented hip stem....
Stability cemented stem....
Porous foundation 440 series....
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: